Table 4 |
|||
|
Monitoring and evaluation indicators, tools and assessment methods: programmatic indicators. |
|||
|
Indicator |
Targets |
Tools |
Research |
|
|
|||
|
1. Identification of high risk individuals |
|||
|
|
|||
|
Proportion of adolescent ANC attendees |
>80% of adolescents attending ANC |
Health facility assessments |
Strategies for delaying pregnancies |
|
|
|||
|
Proportion of primigravidae with late ANC attendance |
<10% attendees |
Health facility assessment |
Reasons for late attendance |
|
|
|||
|
Distance indicators of household residence from main health facility |
Identification of high risk areas |
Household surveys |
Community SP-IPTp distribution |
|
|
|||
|
Antenatal HIV infection |
Prevalence reduction |
Mother to child HIV transmission assessments |
Implementation of HIV prevention strategies |
|
|
|||
|
|
|||
|
2. Antimalarial drug efficacy estimates |
|||
|
|
|||
|
Antimalarial therapeutic efficacy |
Agreed surveillance interval (2–5 years) |
Antimalarial in vivo sensitivity tests |
Comparative drug evaluations |
|
|
|||
|
Proportional reduction in parasitaemia between first antenatal visit and delivery |
New indicator |
Health facility prevalence estimate |
Comparison with birthweight or anaemia outcomes |
|
|
|||
|
Proportion of women with placental infection who have received two SP-IPTp doses |
Assessment in sentinel health facilities |
Case-coverage methodology for determining SP-ITPp efficacy |
Comparison of case-coverage efficacy estimates method with in vivo tests |
|
|
|||
|
Antimalarial post-treatment prophylaxis |
Agreed surveillance interval (2–5 years) |
Antimalarial prophylactic efficacy tests |
Evaluation in aparasitaemic women on IPTp |
|
|
|||
|
|
|||
|
3. Safety indicators |
|||
|
|
|||
|
Inadvertent antimalarial drug exposure in first trimester |
No exposures in asymptomatic women |
Cross-sectional household/health facility surveys |
Prevalence estimates and associated pregnancy outcomes |
|
|
|||
|
Assessment of safety indicators via national and international antimalarial exposure registry |
Establishing functional registry |
Standardized protocol under development by WHO |
Demonstration sites; new methods for drug exposure, ascertainment, congenital anomaly detection |
|
|
|||
|
Brabin et al. Malaria Journal 2008 7(Suppl 1):S6 doi:10.1186/1475-2875-7-S1-S6 |
|||
